JCAR018: Additional Phase I data

Additional data from 3 patients ages 1-30 with relapsed or refractory B cell ALL in the second dose cohort of an open-label, U.S. Phase I trial showed that a single

Read the full 302 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE